Industry News

STAAR Surgical reports 10% increase in Q2 revenue

STAAR Surgical reported a 10% increase in revenue for the second quarter of 2014, from $18.2 million to $20 million, according to a company press release.

Revenues grew 11% on a constant currency basis during the second quarter of 2014 compared with the same period last year, according to the release. Foreign currency exchange reduced sales by $0.1 million during the quarter.

These results included quarterly sales of $12.2 million of STAAR’s Visian ICL product portfolio, and $6.4 million of its IOL products, according to the press release.

Other product sales were $1.4 million, representing a 39% increase compared with the second quarter of last year.

The company’s GAAP net loss was $1.8 million, or $0.05 on a per diluted share basis for the second quarter of 2014, compared with a net income of $278,000, or $0.01 on a per diluted share basis in the second quarter of last year, according to the press release.

STAAR expects second-half growth rates to increase as a result of new product releases and increase IOL supply, the release said.

STAAR Surgical reported a 10% increase in revenue for the second quarter of 2014, from $18.2 million to $20 million, according to a company press release.

Revenues grew 11% on a constant currency basis during the second quarter of 2014 compared with the same period last year, according to the release. Foreign currency exchange reduced sales by $0.1 million during the quarter.

These results included quarterly sales of $12.2 million of STAAR’s Visian ICL product portfolio, and $6.4 million of its IOL products, according to the press release.

Other product sales were $1.4 million, representing a 39% increase compared with the second quarter of last year.

The company’s GAAP net loss was $1.8 million, or $0.05 on a per diluted share basis for the second quarter of 2014, compared with a net income of $278,000, or $0.01 on a per diluted share basis in the second quarter of last year, according to the press release.

STAAR expects second-half growth rates to increase as a result of new product releases and increase IOL supply, the release said.